ORGANIZATION

• JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
  March 10, 2025

• Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
  March 6, 2025

• JPMA President Demands Rethink of Social Security Expenditure Cap
  February 27, 2025

• People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
  February 27, 2025

• Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
  February 26, 2025

• Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
  February 21, 2025

• JPMA to Put Japan’s Social Security Spending Cap Up for Discussion: Exec
  February 21, 2025

• Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
  February 20, 2025

• Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
  February 14, 2025

• US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
  February 10, 2025

• Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
  February 10, 2025

• Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
  February 5, 2025

• Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
  January 29, 2025

• JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
  January 24, 2025

• Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
  January 17, 2025

• JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
  January 14, 2025

• Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
  January 9, 2025

• Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
  January 9, 2025

• FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
  January 7, 2025

• 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
  January 7, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• …
• Next ›
• 最終 »